Bharat Biotech, University of Sydney ink pact for vaccine research collaboration
Vaccines major Bharat Biotech International Ltd on Tuesday said it has entered into a collaboration with the University of Sydney Infectious Diseases Institute to advance vaccine research initiatives, strengthen academic-industry partnerships and augment global efforts to combat infectious diseases.
Vaccines major Bharat Biotech International Ltd on Tuesday said it has entered into a collaboration with the University of Sydney Infectious Diseases Institute to advance vaccine research initiatives, strengthen academic-industry partnerships and augment global efforts to combat infectious diseases.
The company has signed a Memorandum of Understanding (MoU) with the University of Sydney Infectious Diseases Institute (Sydney ID) for the collaboration that aims to build strong sectoral and cross-organisational collaborations to design novel methodologies to tackle future epidemics and infectious diseases, Bharat Biotech said in a statement.
Furthermore, the collaboration will also leverage academia-industry strengths for advancing the science of vaccines and biotherapeutics, it added.
"This agreement reflects our ethos to facilitate collaborative research, foster innovation, and further advance the science vaccine technology," Bharat Biotech Executive Chairman Krishna Ella said.
The collaboration will "leverage the prowess of education, research capabilities to help build a healthier universe and improve people's lives by developing safer vaccine platforms", he said, adding, "most importantly, (it will help) build the talent of young scientists with a passion to innovate".
Sydney ID Deputy Director Professor Jamie Triccas said, "The reputational and societal impacts of developing novel vaccines to eradicate human and animal diseases that are safe, affordable, and effective cannot be overstated. Together with Bharat Biotech International Ltd, we aim to make a lasting impact on global health." Bharat Biotech had played a key role in the combat against COVID-19 with its indigenously developed COVAXIN.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
IRCTC Dividend 2024: Railway PSU announces 200% interim dividend - Check record date and other details
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
02:35 PM IST